Development of a physiologically based pharmacokinetic model for mefloquine and its application alongside a clinical effectiveness model to select an optimal dose for prevention of malaria in young Caucasian children

ConclusionsThe PBPK and clinical effectiveness models are mutually supportive and suggest a prophylactic dose of 62.5  mg weekly in the Caucasian 5–10 kg infant population travelling to endemic countries. This dual approach offers a novel route to dose selection in a vulnerable population, where clinical trials would be difficult to conduct.

Source: British Journal of Clinical Pharmacology - November 5, 2018 Category: Drugs & Pharmacology Authors: Trevor N. Johnson, Yumi Cleary, Neil Parrott, Bruno Reigner, James R. Smith, Stephen Toovey Tags: ORIGINAL ARTICLE Source Type: research